ClinicalTrials.gg
CompletedNCT04537429Updated Oct 6, 2023

A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab

A Phase 1 interventional study of Eptinezumab in Migraine in Children and Migraine, sponsored by H. Lundbeck A/S. Completed at 9 sites in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-10-06.

Sponsored by H. Lundbeck A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2022, 4 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.

Enrollment
21st of 21
28 · median 193
Started
2020
with 1 other
Phase 1
3 of 21
none open now
Registered
9th of 21
by date
Lead sponsor
12 of 21
H. Lundbeck A/S

Among the 21 studies testing eptinezumab in Migraine Disorders, this one is the 21st largest by enrollment, is one of 2 that started in 2020, is one of 3 in phase 1, and was the 9th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About eptinezumab

eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing eptinezumab in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of the study is to investigate how the body absorbs, distributes, and get rid of eptinezumab when given directly into a vein.

Read the detailed description

This is an interventional, open-label pharmacokinetic study with eptinezumab, consisting of a single-dose, 20-week main study period (Part A) and an optional 44-week multiple-dose extension period (Part B).

The main study period includes a single IV infusion of eptinezumab. The optional extension period includes 3 additional eptinezumab infusions 12 weeks apart (reflecting recommended dosing interval in adults), for a total of up to 4 infusions over the course of the study.

At least 32 patients with migraine will be enrolled: 16 patients aged 6 to 11 years, and 16 patients aged 12 to 17 years, inclusive.

03

Conditions studied

  • Migraine in Children
  • Migraine

Browse trials for

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has a diagnosis of migraine with or without aura according to international classification of headache disorders (ICHD)-3 (in the opinion of the investigator) for ≥6 months prior to the Screening Visit and has a frequency of migraine ≥4 migraine days per month for at least 3 months prior to the Screening Visit.

Exclusion criteria

Exclusion Criteria:

  • The patient has been exposed to any monoclonal antibody treatment (including exposure in a study) \<6 months prior to the Screening Visit.

Other in- and exclusion criteria may apply

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Eptinezumab

    Drug: Eptinezumab

Interventions

06

What researchers measure

Primary outcomes

  1. Area under curve (AUC) (0-infinity) eptinezumab

    Area under the plasma concentration curve for eptinezumab from zero to infinity

    Time frame: From dosing to week 20

  2. Cmax eptinezumab

    Maximum observed plasma concentration of eptinezumab

    Time frame: From dosing to week 20

Secondary outcomes

  1. Clearance (CL)

    Plasma clearance

    Time frame: From dosing to week 20

  2. Volume of distribution (Vz)

    Time frame: From dosing to week 20

  3. Development of anti-eptinezumab antibodies (ADA)

    Time frame: From screening to week 12

  4. Characterization of anti-eptinezumab antibodies for neutralizing activity (NAb)

    Time frame: From screening to week 12

07

Study locations

9 sites
  • New England Institute for Clinical Research
    Stamford, Connecticut 06905, United States
  • NW FL Clinical Research Group LLC
    Gulf Breeze, Florida 32561, United States
  • The Premiere Research Institute at Palm Beach Neurology
    West Palm Beach, Florida 33407-3234, United States
  • College Park Family Care Center
    Overland Park, Kansas 66212, United States
  • Michigan Head Pain and Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • Preferred Primary Care Physicians Inc.
    Pittsburgh, Pennsylvania 15236-4604, United States
  • North Texas Institute of Neurology & Headache
    Frisco, Texas 75034, United States
  • Road Runner Research Ltd
    San Antonio, Texas 78249, United States
  • Wasatch Clinical Research
    Salt Lake City, Utah 84107, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Oct 2022, 26 months.

Of 39 industry-sponsored phase 1 interventional studies under Migraine Disorders, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 26 months is above that.

Counting every sponsor, half of 53 studies reached it within 6 months; a quarter within 2 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2020
First posted
Sep 3, 2020
StartActual
Aug 4, 2020
Primary completionActual
Oct 20, 2022
CompletionActual
Aug 21, 2023
Last update
Oct 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04537429
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Sep 3, 2020
Start date
Aug 4, 2020
Primary completion
Oct 20, 2022
Completion
Aug 21, 2023
Last update
Oct 6, 2023

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@Lundbeck.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eptinezumab

Start the discussion